Eli Lilly (LLY)
(Delayed Data from NYSE)
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$776.38 USD
-29.68 (-3.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $774.63 -1.75 (-0.23%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
The Zacks Analyst Blog Highlights : Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy
by Zacks Equity Research
Eli Lilly, Nike, Micron Technology, Bayer Aktiengesellschaft, and Valero Energy are included in today's analyst blog.
Top Analyst Reports for Eli Lilly, NIKE & Micron Technology
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), NIKE, Inc. (NKE) and Micron Technology, Inc. (MU).
Mirati (MRTX) Focuses on Seeking Nod for KRAS Drug Adagrasib
by Zacks Equity Research
Mirati's (MRTX) regulatory filing to the FDA for adagrasib in second-line NSCLC gets a longer-than-expected review period. MRTX is progressing well with the pipeline development for other candidates.
AbbVie's (ABBV) Qulipta Meets Chronic Migraine Study Endpoints
by Zacks Equity Research
AbbVie's (ABBV) new oral anti-CGRP drug, Qulipta, demonstrates potential to reduce monthly migraine days in adults with chronic migraine in a phase III study.
Eli Lilly (LLY) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $259.93, moving -0.65% from the previous trading session.
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients
by Ekta Bagri
Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.
Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $254.17 in the latest trading session, marking a +1.87% move from the prior day.
Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022
by Zacks Equity Research
Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.
United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down
by Zacks Equity Research
United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.
Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals
by Kinjel Shah
Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.
Pharma Stock Roundup: EU Approval to PFE, AZN Products, FDA Nod to LLY New COVID Drug
by Kinjel Shah
FDA grants EUA to Eli Lilly's (LLY) new COVID antibody-drug, bebtelovimab. AstraZeneca's (AZN) Saphnelo and Pfizer's (PFE) Ngenla (somatrogon) and Apexxnar vaccine get approval in Europe
GSK vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GSK vs. LLY: Which Stock Is the Better Value Option?
ImmunoGen (IMGN) Up on Licensing Deal With Lilly Worth $1.7 B
by Zacks Equity Research
ImmunoGen (IMGN) inks a licensing agreement with Eli Lilly, granting the latter rights to develop and commercialize ADCs directed toward targets selected by Lilly. Stock up.
Biohaven (BHVN) Migraine Drug Meets Study Goals in China
by Zacks Equity Research
Biohaven (BHVN) and partner Pfizer announce positive top-line results from a phase III study on rimegepant for the acute treatment of migraine. The study meets the co-primary endpoints.
ProQR (PRQR) Plunges as Lead Drug Fails in Phase II/III Study
by Zacks Equity Research
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
Gilead (GILD) Veklury Retains Activity Against Omicron Variant
by Zacks Equity Research
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
Lilly's (LLY) COVID-19 Drug Gets FDA Nod for Emergency Use
by Zacks Equity Research
Lilly's (LLY) new antibody-drug, bebtelovimab is authorized to treat certain non-hospitalized adults and pediatric patients with mild-to-moderate COVID-19 who are at high risk of progressing to severe disease
The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly
by Zacks Equity Research
Pfizer, AstraZeneca, Glaxo, Sanofi¿¿¿s and Eli Lilly are highlighted in this Analyst Blog.
The Zacks Analyst Blog Highlights: Eli Lilly and Company, Union Pacific Corporation, and Freeport-McMoRan Inc
by Zacks Equity Research
Eli Lilly and Company, Union Pacific Corporation, and Freeport-McMoRan Inc. are highlighted in this Analyst Blog.
Top Stock Reports for Eli Lilly, Union Pacific & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX).
Lilly (LLY) Gets FDA Panel Advice for New Study on Sintilimab
by Zacks Equity Research
An FDA advisory for Lilly's (LLY) partner Innovent Biologics calls for conducting a new study on its first-line lung cancer candidate, sintilimab, for gaining approval for the same in the United States.
Pharma Stock Roundup: PFE, AZN, GSK's Q4 Earnings, FDA Updates for SNY, LLY
by Kinjel Shah
Pfizer (PFE), AstraZeneca (AZN) and Glaxo (GSK) report fourth-quarter results. FDA approves Sanofi's (SNY) new rare blood disorder drug.